HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by CESPEDES, S. Articles by OÑATE, A. Search for Related Content PubMed PubMed Citation Articles by CESPEDES, S. Articles by OÑATE, A. Agricola Articles by CESPEDES, S. Articles by OÑATE, A.

Identification and partial characterisation of a new protective antigen of Brucella abortus

Department of Microbiology, Faculty of Biological Sciences, Universidad de Concepción, Concepción and *Department of Immunology, Faculty of Medicine, Universidad Austral, Valdivia, Chile

Corresponding author: Dr A. Oñate (e-mail: aonate{at}udec.cl).

Received 9 Feb. 1999; revised version accepted 28 July 1999.

Abstract

Two novel Brucella abortus proteins were isolated from B. abortus strain RB51 and their immunological properties were determined. These proteins precipitated in the 40–60% saturated concentration range of ammonium sulphate and had a molecular mass of 32.2 kDa and 22.9 kDa, respectively. Both were able to induce a strong in-vitro blast transformation in lymphoid cells obtained from mice previously sensitised with a crude brucella protein extract. The protection studies showed that the 22.9-kDa protein used as a protective immunogen was as effective as the live B. abortus RB51 vaccine but the 32.2-kDa protein had a poor protective effect under similar conditions. The amino-terminal sequence of the 22.9-kDa and 32.2-kDa proteins was determined and analysed in a database. The lack of homology with other known B. abortus proteins indicated that both proteins were novel antigens.

This article has been cited by other articles:

				J. Cassataro, C. A. Velikovsky, L. Bruno, S. M. Estein, S. de la Barrera, R. Bowden, C. A. Fossati, and G. H. Giambartolomei Improved Immunogenicity of a Vaccination Regimen Combining a DNA Vaccine Encoding Brucella melitensis Outer Membrane Protein 31 (Omp31) and Recombinant Omp31 Boosting Clin. Vaccine Immunol., July 1, 2007; 14(7): 869 - 874. [Abstract] [Full Text] [PDF]

				J. Cassataro, S. M. Estein, K. A. Pasquevich, C. A. Velikovsky, S. de la Barrera, R. Bowden, C. A. Fossati, and G. H. Giambartolomei Vaccination with the Recombinant Brucella Outer Membrane Protein 31 or a Derived 27-Amino-Acid Synthetic Peptide Elicits a CD4+ T Helper 1 Response That Protects against Brucella melitensis Infection Infect. Immun., December 1, 2005; 73(12): 8079 - 8088. [Abstract] [Full Text] [PDF]

				C. A. Velikovsky, F. A. Goldbaum, J. Cassataro, S. Estein, R. A. Bowden, L. Bruno, C. A. Fossati, and G. H. Giambartolomei Brucella Lumazine Synthase Elicits a Mixed Th1-Th2 Immune Response and Reduces Infection in Mice Challenged with Brucella abortus 544 Independently of the Adjuvant Formulation Used Infect. Immun., October 1, 2003; 71(10): 5750 - 5755. [Abstract] [Full Text] [PDF]

				J. Ko and G. A. Splitter Molecular Host-Pathogen Interaction in Brucellosis: Current Understanding and Future Approaches to Vaccine Development for Mice and Humans Clin. Microbiol. Rev., January 1, 2003; 16(1): 65 - 78. [Abstract] [Full Text] [PDF]